Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | CPA1 | P15085 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22469164 | 0.81 | CPA1 (0.37) | ITGB3ITGA2BTSHRSMN1; SMN2CPA1 | |
| SCHEMBL2370207 | 0.81 | CPA1 (0.37) | ITGB3ITGA2BTSHRSMN1; SMN2CPA1 | |
| SCHEMBL263735 | 0.77 | TDP1 (0.38) | SMN1; SMN2 | |
| SCHEMBL29662747 | 0.77 | ASAH1 (0.34) | ITGB3ITGA2BTSHRSMN1; SMN2ATM | |
| SCHEMBL5823623 | 0.72 | TSHR (0.45) | TSHRCPA1CNR1 | |
| SCHEMBL263369 | 0.69 | — | — | |
| SCHEMBL17866155 | 0.67 | CPA1 (0.35) | ITGB3ITGA2BCPA1 | |
| SCHEMBL3609476 | 0.67 | GRIK1 (0.33) | CPA1 | |
| SCHEMBL3609473 | 0.67 | GRIK1 (0.33) | CPA1 | |
| SCHEMBL3642955 | 0.67 | GRIK1 (0.33) | CPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168131-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168131-A1 | NOVEL COMPOUNDS | HTR3B, HNMT, TPMT | ITGB3 490/4885ITGA2B 511/4885TSHR 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.